Nostrum Laboratories and CEO to Pay Up to $50 Million to Settle False Claims Act Claims with DOJ
Nostrum Laboratories Inc. and its CEO, Nirmal Mulye, Ph.D., have agreed to a settlement of up to $50 million to resolve allegations that they violated the False Claims Act by knowingly underpaying Medicaid rebates for Nostrum's drug Nitrofurantoin Oral Suspension (Nitro OS). The settlement, which includes a minimum payment of $3,825,000, is contingent on certain financial conditions.